Bialer M, Friedman M, Dubrovsky J
Biopharm Drug Dispos. 1984 Jan-Mar;5(1):1-10. doi: 10.1002/bdd.2510050102.
A new sustained release dosage form of valproic acid (VPA) was developed. The new sustained release dosage form was administered (twice, with and without food) to five dogs in comparison to a standard tablet (Depakine, Labaz) and an i.v. preparation of the drug. Drug level monitoring in the plasma was performed by a GLC assay. Results indicate that the sustained release formulation exhibited a more prolonged and uniform absorption rate, yielded more sustained plasma levels after ingestion, and showed an overall bioavailability of 0.84 (95 per cent C.I. = 0.72, 0.96) relative to an equivalent dose of a conventional tablet.
研发出了一种新型丙戊酸（VPA）缓释剂型。将这种新型缓释剂型（分别在进食和未进食情况下给药两次）给予五只狗，与标准片剂（德巴金，拉巴兹公司）和该药物的静脉注射制剂进行比较。通过气相色谱分析法对血浆中的药物水平进行监测。结果表明，该缓释制剂呈现出更持久且均匀的吸收速率，摄入后产生更持久的血浆水平，相对于同等剂量的传统片剂，其总体生物利用度为0.84（95%置信区间 = 0.72, 0.96）。
